Opportunity

NYC Passport #81626Y0812

NYC DOHMH Sole Source Procurement for Illumina MiSeq Instruments, Nextera Kits, and Related Products

Posted

March 24, 2026

Respond By

April 03, 2026

Identifier

81626Y0812

NAICS

334516

The New York City Department of Health and Mental Hygiene (DOHMH) is pursuing a six-year sole source procurement with Illumina Inc. for advanced laboratory testing equipment and supplies to support public health initiatives. - Government Buyer: - New York City Department of Health and Mental Hygiene (DOHMH) - NYC Public Health Laboratory - OEM Highlight: - Illumina Inc. is the sole manufacturer and provider for all requested products and services - Products and Services Requested: - MiSeq sequencing instruments for clinical and environmental testing - Nextera assay kits for whole genome sequencing - Reagents, equipment, instruments, and other supplies for pathogen detection - Maintenance and support services for Illumina instruments and equipment - Applications and Use Cases: - Detection of foodborne pathogens (Listeria, Salmonella, STECs) - Detection of waterborne pathogens (Legionella) - Identification of drug-resistant bacteria (Shigella, N. gonorrhea) - Surveillance of mosquito-transmissible viruses (Zika) - Unique Requirements: - Sole source justification: Illumina Inc. is the only provider of these specific products and services - Open to Expressions of Interest from firms that can legally provide equivalent products - Estimated Contract Value: - $6,600,000 over six years

Description

The Department of Health and Mental Hygiene (DOHMH) of New York City intends to negotiate a six-year agreement with Illumina Inc. for the purchase of MiSeq Instruments, Nextera assay kits, reagents, equipment, instruments, and other supplies, including maintenance and services. These products will be used by the Public Health Laboratory to conduct clinical and environmental testing for various pathogens and viruses such as foodborne pathogens, waterborne pathogens, drug-resistant bacteria, and mosquito-transmissible viruses including Zika. Illumina Inc. is identified as the sole provider and manufacturer of these testing products. The contract is estimated to start on January 1, 2027, and end on December 31, 2032, with an estimated value of $6.6 million.

View original listing

Get AI summaries, saved searches, and real-time alerts for new opportunities. Sign up free · Sign in